Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,390.00    108.00 (4.73%)
Bid:
2,380.00
Ask:
2,384.00
Spread: 4.00 (0.168%)
Market Cap: £7.67b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

24 Jun 2025 07:00

RNS Number : 0410O
Bunzl PLC
24 June 2025
 

24 June 2025

 BUNZL PRE-CLOSE STATEMENT

Trading in-line with expectations; acquisition agreed in Brazil

 

Bunzl plc, the specialist international distribution and services Group, is updating the market today prior to entering its closed period for the six months ending 30 June 2025.

Group revenue over the period is expected to be approximately 4% higher than the prior year, at constant exchange rates, and up to 1% higher at actual exchange rates. Group revenue growth at constant exchange rates is expected to be driven by acquisitions, net of disposals, and with broadly flat underlying revenue over the period1. We expect Group operating margin over the period to be in-line with previously published guidance at around 7.0%, with the expected Group adjusted operating profit decline also in-line with expectations.

2025 guidance

As per our statement on 16th April, the Group expects moderate revenue growth in 2025, at constant exchange rates, driven by announced acquisitions and broadly flat underlying revenue. Group operating margin for the year is expected to be moderately below 8.0%, compared to 8.3% in 2024. The Group's second half operating margin is seasonally higher and expected to benefit from actions taken.

Capital allocation update

In May, Bunzl signed an agreement to acquire Solupack, a Brazilian distributor of own brand packaging solutions to the food industry. In 2024 the business generated revenue of BRL 106 million (c.£ 15 million), and alongside our existing business will enhance our offering to customers. The acquisition is subject to competition authority clearance.

At the end of June we expect our leverage to be around 2.0 times, consistent with our aim to be towards the lower end of our target range of 2.0 to 2.5 times adjusted net debt to EBITDA by the end of 2025, after potential acquisition spend.

 

Commenting on today's announcement, Frank van Zanten, Chief Executive Officer of Bunzl, said:

"Alongside a macroeconomic backdrop that remains uncertain, the Group is trading in-line with our expectations. Actions are underway to improve performance in the Group, particularly in our largest business in North America and in Continental Europe, and we anticipate improvement in the second half of the year.

I am also pleased to welcome Solupack to the Bunzl family today, our third acquisition of the year, with our pipeline remaining active. The Group's compounding growth strategy and resilient business model underpin Bunzl's long-term track record of delivery and the Group continues to be well placed to navigate periods of macroeconomic uncertainty given our focus on essential products, the depth of our customer and supplier relationships and our sector and geographic diversification."

Enquiries:

 Bunzl plc

 Frank van Zanten, Chief Executive Officer

 Richard Howes, Chief Financial Officer

 Sunita Entwisle, Head of Investor Relations and Communications

 Tel: +44 (0)20 7725 5000

Teneo

Martin Robinson

Giles Kernick

Tel: +44 (0)20 7353 4200

1. The impact of fewer trading days is also expected to have a slight impact on revenue.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBUGDLIXDDGUX
Date   Source Headline
3rd Jun 202610:45 amRNSDirector/PDMR Shareholding
1st Jun 202610:15 amRNSTotal Voting Rights
1st Jun 202610:00 amRNSAdmission to Trading
8th May 20264:13 pmRNSDirector/PDMR Shareholding
7th May 20262:43 pmRNSDirector/PDMR Shareholding
6th May 202610:05 amRNSDirector/PDMR Shareholding
1st May 202611:15 amRNSTotal Voting Rights
22nd Apr 20264:15 pmRNSResult of AGM
22nd Apr 20267:00 amRNSTrading Statement
13th Apr 20264:00 pmRNSDirector/PDMR Shareholding
9th Apr 202612:01 pmRNSDirector/PDMR Shareholding
1st Apr 20264:00 pmRNSDirector/PDMR Shareholding
1st Apr 202611:00 amRNSTotal Voting Rights
31st Mar 20264:50 pmRNSDirector/PDMR Shareholding
20th Mar 20262:28 pmRNSDirector/PDMR Shareholding
18th Mar 20265:26 pmRNSDirector/PDMR Shareholding
17th Mar 20264:20 pmRNSAnnual Financial Report
16th Mar 20263:00 pmRNSDirector/PDMR Shareholding
16th Mar 20263:00 pmRNSDirector/PDMR Shareholding
11th Mar 20264:00 pmRNSDirector/PDMR Shareholding
11th Mar 20264:00 pmRNSDirector/PDMR Shareholding
10th Mar 20263:30 pmRNSDirector Declaration
10th Mar 20263:30 pmRNSDirector Declaration
9th Mar 202610:20 amRNSDirector/PDMR Shareholding
5th Mar 20265:15 pmRNSDirector/PDMR Shareholding
4th Mar 20264:00 pmRNSDirector/PDMR Shareholding
3rd Mar 20264:45 pmRNSDirector/PDMR Shareholding
2nd Mar 202611:00 amRNSTotal Voting Rights
2nd Mar 202610:00 amRNSDividend Declaration
2nd Mar 20267:00 amRNSFinal Results
3rd Feb 20265:00 pmRNSDirector/PDMR Shareholding
2nd Feb 202612:45 pmRNSTotal Voting Rights
13th Jan 20265:00 pmRNSDirector/PDMR Shareholding
7th Jan 20265:15 pmRNSDirector/PDMR Shareholding
6th Jan 202611:15 amRNSDirector/PDMR Shareholding
2nd Jan 202610:45 amRNSTotal Voting Rights
17th Dec 20257:00 amRNSTrading Statement
3rd Dec 202512:00 pmRNSDirector/PDMR Shareholding
1st Dec 202511:00 amRNSTotal Voting Rights
27th Nov 20259:00 amRNSAdditional Listing
26th Nov 20253:34 pmRNSPublication of Admission Particulars.
21st Nov 20255:30 pmRNSHolding(s) in Company
17th Nov 20255:34 pmRNSHolding(s) in Company
13th Nov 20259:00 amRNSAdditional Listing
5th Nov 20259:45 amRNSDirector/PDMR Shareholding
3rd Nov 20254:00 pmRNSHolding(s) in Company
3rd Nov 20253:29 pmRNSTotal Voting Rights
3rd Nov 20259:30 amRNSBlock listing Interim Review
3rd Nov 20257:00 amRNSTransaction in Own Shares
31st Oct 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.